title: Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?
abstract: Treatment for advanced prostate cancer has and will continue to grow increasingly complex, owing to the introduction of multiple new therapeutic approaches with the potential to substantially improve outcomes for this disease. Agents that modulate the patient's immune system to fight prostate cancer - immunotherapeutics - are among the most exciting of these new approaches. The addition of antigen-specific immunotherapy to the treatment of castration-resistant prostate cancer (CRPC) has paved the way for additional research that seeks to augment the activity of the immune system itself. The monoclonal antibody ipilimumab, approved in over 40 countries to treat advanced melanoma and currently under phase 2 and 3 investigation in prostate cancer, is thought to act by augmenting immune responses to tumors through blockade of cytotoxic T-lymphocyte antigen 4, an inhibitory immune checkpoint molecule. Ipilimumab has been studied in seven phase 1 and 2 clinical trials that evaluated various doses, schedules, and combinations across the spectrum of patients with advanced prostate cancer. The CRPC studies of ipilimumab to date suggest that the agent is active in prostate cancer as monotherapy or in combination with radiotherapy, docetaxel, or other immunotherapeutics, and that the adverse event profile is as expected given the safety data in advanced melanoma. The ongoing phase 3 program will further characterize the risk/benefit profile of ipilimumab in chemotherapy-naïve and -pretreated CRPC.
authors: Department of Medicine, University of California, San Francisco, California 94143, USA. edward.cha@ucsf.edu
authors: Edward
authors: E
authors: Cha
authors: Eric J
authors: EJ
authors: Small
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D060908:CTLA-4 Antigen / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D000074324:Ipilimumab; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000276:immunology*; D015398:Signal Transduction
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; D000074324:Ipilimumab
keywords: Castration-resistant prostate cancer; checkpoint blockade; immune response; immunotherapy; ipilimumab
references: Clin Cancer Res. 2011 Jul 15;17(14):4622-8
references: 21467163
references: Cancer Immunol Immunother. 2013 Feb;62(2):245-56
references: 22878899
references: Clin Cancer Res. 2009 Sep 1;15(17):5591-8
references: 19671877
references: Nat Rev Immunol. 2010 Aug;10(8):580-93
references: 20651745
references: J Immunol Methods. 2009 Aug 31;348(1-2):9-17
references: 19552894
references: N Engl J Med. 2011 Jun 30;364(26):2517-26
references: 21639810
references: J Transl Med. 2011 Nov 28;9:204
references: 22123319
references: Oncologist. 2008 Dec;13(12):1246-54
references: 19056856
references: J Natl Compr Canc Netw. 2010 Feb;8(2):162-200
references: 20141676
references: Clin Cancer Res. 2011 Aug 15;17(16):5233-8
references: 21700764
references: Front Biosci. 2007 Sep 01;12:4957-71
references: 17569623
references: Eur J Immunol. 2005 Jan;35(1):66-75
references: 15597325
references: Clin Cancer Res. 2007 Mar 15;13(6):1810-5
references: 17363537
references: Clin Cancer Res. 2007 Dec 1;13(23):6947-58
references: 18056169
references: Semin Oncol. 2010 Oct;37(5):533-46
references: 21074069
references: J Urol. 2008 Jun;179(6):2181-5; discussion 2185-6
references: 18423743
references: N Engl J Med. 2010 Aug 19;363(8):711-23
references: 20525992
references: Nat Rev Cancer. 2007 Feb;7(2):95-106
references: 17251916
references: Lancet Oncol. 2012 May;13(5):501-8
references: 22326924
references: J Clin Oncol. 2010 Mar 1;28(7):1099-105
references: 20100959
references: Lab Invest. 2009 Feb;89(2):142-51
references: 19079323
references: Cancer Res. 2009 Jan 15;69(2):609-15
references: 19147575
references: J Clin Oncol. 2011 Sep 20;29(27):3677-85
references: 21825260
references: J Transl Med. 2012 Jul 12;10:146
references: 22788688
references: Nat Med. 2007 Sep;13(9):1050-9
references: 17704786
references: Curr Opin Immunol. 2008 Oct;20(5):504-11
references: 18573340
references: Lancet Oncol. 2010 Feb;11(2):155-64
references: 20004617
references: J Clin Oncol. 2017 Jan;35(1):40-47
references: 28034081
references: N Engl J Med. 2010 Jul 29;363(5):411-22
references: 20818862
references: Lancet Oncol. 2012 May;13(5):509-17
references: 22326922